Letter to the Editor: Therapies for Osteogenesis Imperfecta

Authors

  • Sandra Sousa Rheumatology Department. Hospital Garcia de Orta. Almada. Portugal.
  • Fátima Godinho Rheumatology Department. Hospital Garcia de Orta. Almada. Portugal.
  • Maria José Santos Rheumatology Department. Hospital Garcia de Orta. Almada. Portugal. Rheumatology Research Unit. Instituto de Medicina Molecular. Lisbon. Portugal.

DOI:

https://doi.org/10.20344/amp.8461

Keywords:

Osteogenesis Imperfecta, Portugal, Zoledronic Acid

Abstract

N/A.

Downloads

Download data is not yet available.

Downloads

Published

2017-02-27

How to Cite

1.
Sousa S, Godinho F, Santos MJ. Letter to the Editor: Therapies for Osteogenesis Imperfecta. Acta Med Port [Internet]. 2017 Feb. 27 [cited 2024 Nov. 22];30(2):156-7. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/8461

Issue

Vol. 30 No. 2 (2017): February

Section

Letters to the Editor

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC